Brage E. Terán

Concordance between RAS and BRAF mutational status determination in ctDNA and tissue in patients with mCRC

Background Liquid biopsy is a tool that enables identification of diagnostic, prognostic and predictive biomarkers of response to treatment in circulating tumour DNA (ct...

Hernández J. Cruz ;

Brage E. Terán ;

Tocino R. Vidal ;

Francoso A. Rodrígues ;

López B. Rivas ;

Gutiérrez A. López ;

Pérez L. Figuero ;

Ampuero J. Claros ;

García B. Cigarral ;

Sánchez E. Fonseca ;

06/27/2022

Fluoropyrimidine- and irinotecan-induced toxicity profile associated with mutations in DPYD and UGT1A1 genes

Background Fluoropyrimidines are a mainstay in the treatment of gastrointestinal tumours (GIT), although they can sometimes produce severe toxicity, usually related to p...

Brage E. Terán ;

Tocino R. Vidal ;

García B. Cigarral ;

Sánchez E. Fonseca ;

Martín M. Navarro ;

Jung D. Heredero ;

Berrocal B. García ;

Jiménez M. Navalón ;

06/27/2022

Germline testing in pancreatic adenocarcinoma

Background Pancreatic ductal adenocarcinoma (PDAC) remains a challenging disease to treat. Despite advances in medical therapies, the 5-year survival rate remains below ...

Martín M. Navarro ;

Gómez T. Martín ;

Sarmiento R. González ;

Tamayo R. Seijas ;

Brage E. Terán ;

Tocino R. Vidal ;

Gutiérrez A. López ;

Sánchez E. Fonseca ;

Hernández J. Cruz ;

Tapia E. Sánchez ;

García J. Pérez ;

06/27/2022

Efficacy and safety of anti-PD-1 agents in patients with dMMR metastatic solid tumours: A retrospective, real-world study

Background Immune checkpoint inhibitors (ICIs) have been a revolution in the treatment of solid tumours with a significant increase in overall survival rates. High micro...

Brage E. Terán ;

Tocino R. Vidal ;

Gutiérrez A. López ;

Pérez L. Figuero ;

Sánchez E. Fonseca ;

Gómez A. Moreno ;

Mejorada R. Lozano ;

06/27/2022